UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000058122
Receipt number R000066437
Scientific Title Prediction of Atherosclerotic Calcified Plaque Progression Using 18F-NaF PET/CT: A Systematic Review and Meta-analysis
Date of disclosure of the study information 2025/06/10
Last modified on 2025/06/11 19:29:01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Using 18F-NaF PET/CT to Predict the Progression of Artery Calcification: A Plain-Language Summary of Research

Acronym

18F-NaF PET/CT for Predicting Calcified Plaque Progression

Scientific Title

Prediction of Atherosclerotic Calcified Plaque Progression Using 18F-NaF PET/CT: A Systematic Review and Meta-analysis

Scientific Title:Acronym

18F-NaF PET/CT for Predicting Calcified Plaque Progression

Region

Japan


Condition

Condition

Atherosclerosis

Classification by specialty

Cardiology Radiology Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The objective of this study is to systematically evaluate whether there is a significant correlation between 18F-NaF uptake intensity in calcified atherosclerotic plaques, as measured by the tissue-to-background ratio (TBR) on 18F-NaF PET/CT, and the progression of calcification quantified by changes in Agatston score units. Through a meta-analysis of relevant studies, we aim to clarify the strength and consistency of this relationship, which may help establish 18F-NaF uptake as a predictive imaging biomarker for arterial calcification progression.

Basic objectives2

Others

Basic objectives -Others

To evaluate the correlation between 18F-NaF uptake intensity and the progression of calcification scores

Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Meta-analysis of the correlation between 18F-NaF uptake intensity (TBR: tissue-to-background ratio) and the increase in Agatston score units

Key secondary outcomes



Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Not applicable (meta-analysis)

Key exclusion criteria

Not applicable (meta-analysis)

Target sample size



Research contact person

Name of lead principal investigator

1st name Yoshinobu
Middle name
Last name Ishiwata

Organization

Yokohama City University Hospital

Division name

Department of Nuclear Medicine

Zip code

2360004

Address

3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, Japan

TEL

0457872800

Email

ishi_y@yokohama-cu.ac.jp


Public contact

Name of contact person

1st name Yoshinobu
Middle name
Last name Ishiwata

Organization

Yokohama City University Hospital

Division name

Department of Nuclear Medicine

Zip code

2360004

Address

3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, Japan

TEL

0457872800

Homepage URL


Email

ishi_y@yokohama-cu.ac.jp


Sponsor or person

Institute

Yokohama City University Hospital

Institute

Department

Personal name



Funding Source

Organization

No funding

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Not applicable (meta-analysis)

Address

Not applicable (meta-analysis)

Tel

Not applicable (meta-analysis)

Email

Not applicable (meta-analysis)


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2025 Year 06 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2025 Year 06 Month 09 Day

Date of IRB

2025 Year 06 Month 10 Day

Anticipated trial start date

2025 Year 06 Month 10 Day

Last follow-up date

2027 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This study is a systematic review and meta-analysis based on previously published data. No new patient recruitment or intervention is involved. No funding was received for this work. Ethical approval was deemed not applicable.


Management information

Registered date

2025 Year 06 Month 09 Day

Last modified on

2025 Year 06 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066437